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A comparative study of standardized
quantitative and visual assessment for
predicting tumor volume and outcome in
newly diagnosed diffuse large B-cell
lymphoma staged with 18F-FDG PET/CT
Lars C. Gormsen1* , Mikkel H. Vendelbo1,7, Mette Abildgaard Pedersen1, Ate Haraldsen1, Karin Hjorthaug1,
Trond Velde Bogsrud1,6, Lars J. Petersen3, Karen Juul Jensen4, Rasmus Brøndum2 and Tarec C. El-Galaly2,5
Abstract
Background: Semi-automated quantitative measurement of metabolic tumor volume (MTV) for prognosis in diffuse
large B-Cell lymphoma (DLBCL) has gained considerable interest lately. However, simple tumor volume measures
may be inadequate for assessment of prognosis in DLBCL as other characteristics such as growth pattern and
metabolic heterogeneity may be just as important. In addition, MTV measurements require delineation of tumor
lesions by semi-automated software, which can be time-consuming. We hypothesized that a simple visual
assessment of tumor volume performs as well as standardized MTV measurements in DLBCL prognostication.
Materials and methods: Quantitative and visual analyses of pre-therapy 18F-FDG PET/CT scans in 118 patients
with newly diagnosed DLBCL were conducted. Quantitative analyses were performed using Hermes TumourFinder®
to obtain MTV2.5 (SUV 2.5 cut-off) and MTV41 (41% SUVmax isocontour cut-off). Visual assessments included a binary
prediction (good/poor prognosis) as well as tumor burden based on a visual analog scale (MTVVAS) and an
estimated volume (eMTV). Three experienced nuclear medicine physicians who were blinded to clinical outcome
performed visual evaluations. Progression-free survival was evaluated by Kaplan-Meier curves and log-rank test.
Inter-observer variability was evaluated by Fleiss’ kappa for multiple observers.
Results: In the quantitative analysis, a ROC-determined MTV2.5 cut-off (log-rank p = 0.11) seemed to outperform
MTV41 (log-rank p = 0.76) for PFS prediction. TLG2.5 (log-rank p = 0.14) and TLG41 (log-rank p = 0.34) were not
associated with outcomes. By visual analysis, all three reviewers were able to stratify patients into good/poor
prognosis (reviewer A log-rank p = 0.002, reviewer B log-rank p = 0.016, and reviewer C log-rank p = 0.012) with fair
inter-observer agreement (Fleiss’ kappa 0.47). MTVVAS and eMTV were not consistently correlated with the outcome.
Conclusion: Predictions of outcome after first-line treatment for DLBCL were surprisingly good when left to the
unsupervised, subjective judgment of experienced readers of lymphoma 18F-FDG-PET/CT. The study highlights the
importance of non-standardized clinical judgments and shows potential loss of valuable prognostic information
when relying solely on semi-automated MTV measurements.
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Background
Diffuse large B-cell lymphoma (DLBCL) is the most
common type of non-Hodgkin lymphoma in the West-
ern world. The majority of patients with DLBCL respond
to standard immunochemotherapy with a combination
of the drugs rituximab, cyclophosphamide, doxorubicin
hydrochloride (hydroxydaunorubicin), vincristine sulfate,
and prednisone (R-CHOP), but 30–40% of the patients
are refractory or relapse following initial response [1].
These patients have dismal outcomes and only a minor-
ity can be cured by salvage high-dose therapy and au-
tologous stem cell transplantation [2, 3]. No major
progress has been made in the treatment of DLBCL
since the introduction of rituximab. Attempts to im-
prove outcomes by intensifying chemotherapy and
rituximab-dosing schedules have failed [4–10]. A treat-
ment escalation strategy based on early PET/CT re-
sponse did not improve outcomes in poor responders
over and above what was achieved by continuing stand-
ard therapy [11]. Also, the predictive value of interim
PET/CT in DLBCL, unlike in Hodgkin lymphoma [12],
remains controversial [11]. The key to improving out-
comes in DLBCL may reside in better risk stratification
of DLBCL using an integrative approach that combines
baseline clinical risk factors, genomic features, and early
treatment response [13, 14]. Combinations of tumor vol-
ume measurements on baseline PET/CT and early treat-
ment response have been proposed to identify high-risk
DLBCL patients likely to fail standard therapy [14]. Pro-
viding metabolic tumor volume measurements (quanti-
tative PET/CT), however, is time-consuming and
requires highly standardized algorithms for image acquisi-
tion and reconstruction. Furthermore, relying increasingly
on “automatization” for prognostics minimizes the influ-
ence of clinical judgments by readers with years of experi-
ence. Numerous automated or machine learning-based
algorithms for outcome prediction, particularly in radi-
ology have been proposed in the past decade; however,
only few have been found to be on par or outperform
human-level performance [15]. To test the superiority of
quantitative PET/CT over simple and unsupervised as-
sessment of prognosis by experienced nuclear medicine
specialists, we compared the prognostic value of both
methods in a consecutive cohort of 118 patients.
Methods
One hundred and eighteen patients with newly diag-
nosed DLBCL treated with R-CHOP/R-CHOP-like ther-
apy and undergoing diagnostic work-up including
baseline 18F-FDG PET/CT in the period 2007–2012 at
Aalborg University Hospital were included in this retro-
spective study. Clinical information including outcome
parameters was collected from medical records. The Da-
nish Data Protection agency (ref 1-16-02-88-15) and the
Danish Ministry of Health approved the study (ref
3-3013-860/1/).
PET/CT acquisition
Staging 18F-FDG PET/CT scans were carried out after a
6-h fast on a GE Discovery VCT 710 integrated PET/CT
system in accordance with local protocols and manufac-
turer guidelines. Images from the base of the skull to the
proximal thigh were acquired a median of 71 (range 57–
166) minutes after injection of 4MBq/kg 18F-FDG and
were reconstructed using iterative reconstruction.
Quantitative image analysis (Table 1)
18F-FDG PET/CT images were analyzed by author LCG
using Hybrid Viewer (Hermes Medical Solutions,
Sweden) with the plug-in TumourFinder. Lymphoma le-
sions were segmented using both a SUV > 2.5 threshold
(SUV2.5) as well as > 41% of the SUVmax (SUV41)
thresholding. Quantitation parameters metabolic tumor
volume (MTV2.5 and MTV41) and total lesion glycolysis
(TLG2.5 and TLG41) were recorded for both segmenta-
tion methods.
Visual image analysis (Table 1)
Three experienced (> 10 years) nuclear medicine physi-
cians (A.H., T.V.B., and K.H.) blinded to clinical infor-
mation except patient age performed visual analysis of
images. Observers were asked to rate the following ten-
tatively predictive parameters: (1) prognosis (poor/favor-
able), (2) tumor volume estimate (eMTV) (in milliliters),
and (3) tumor volume (MTVvas) (visual analog score;
VAS, 1–9). Observers were asked to restrict the time
spent evaluating these parameters to a maximum of 30 s
per evaluation in order to reflect the intuitive interpret-
ation of the images. Figure 1 depicts the VAS scale used
by our reviewers as well as examples of patients with
poor and favorable prognosis. To visually assess progno-
sis, reviewers were asked to take into account tumor
heterogeneity, tumor volume, infiltration into adjoining
tissue, extra-nodal spread, and diffuse involvement of,
e.g., the pleura or peritoneum.
In case of disagreement between reviewers, prognosis
was analyzed as a trichotomous variable (favorable/inter-
mediate/poor), whereas eMTV and MTVvas were aver-
aged for all reviewers.
Statistics
Fleiss’ kappa was used to evaluate the inter-observer
variability when reporting the subjective assessment of
prognosis, while the variability for MTVvas and eMTV
was evaluated using the intra-class correlation (ICC).
For MTVVAS, we used the ICC described in [16] while
the ICC for absolute agreement between a random sam-
ple of readers was used for eMTV (ICC2 from the
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R-package psych). The Pearson correlation coefficient
was used to measure consistency between MTV values
obtained by the automated software (MTV2.5 and
MTV41) and visual estimates (eMTV).
Survival analyses were performed according to prog-
nosis subjectively assessed (good/bad), eMTV, MTVvas,
MTV2.5, MTV41, TLG2.5, and TLG41. Progression-free
survival (PFS) was defined as the time from diagnosis to
relapse/progression or death from any cause. Overall
survival (OS) was defined as the time from diagnosis to
death from any cause. Optimal PFS cut-offs for continu-
ous variables were determined with receiver operating
Table 1 Semi-automated methods and visual assessment of tumor volume and prognosis
Method Semi-automated measurements Visual assessment
MTV2.5 MTV41 eMTV MTVVAS Prognosis
Description Metabolic tumor
volume delineation
> SUV 2.5
Metabolic tumor
volume delineation >
41% of SUVmax
Metabolic tumor
volume assessed
visually
Degree of metabolic
tumor volume assessed
on VAS scale
Prognosis assessed visually based on
volume, heterogeneity, involvement of
extra-nodal organs
Parameter Continous (ml) Continous (ml) Continous (ml) Continous (1–9) Dichotomous (poor/favorable)
Fig. 1 Metabolic tumor burden assessed on a VAS scale with representative examples of patients graded as 1, 5, and 9 (a). All reviewers used
these examples to grade individual cases in the study. b An example of a patient with a poor prognosis based on the widespread peritoneal
lymphomatosis, bulky disease, and high metabolic tumor volume. Pointedly, the peritoneal lymphomatosis may be difficult to accurately quantify
using semi-automatic tumor delineation tools whereas the severity of disease is readily perceived by visual inspection using a maximum intensity
projection FDG PET/CT. c A patient with limited mediastinal disease used as an example of a patient with favorable prognosis
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characteristics (ROC) curves for three-year survival and
three-year progression-free survival as the point with the
shortest distance from (0, 1). Survival curves were com-
puted using the Kaplan-Meier method and differences
were tested using the log-rank test. Statistics were calcu-
lated using R version (3.4.3).
Results
A total of 118 patients (76 males and 42 females) with
median age 66 (range 18–88) were included (Table 2).
According to the international prognostic index (IPI), 60
patients (50.8%) were low/low-intermediate risk, 29
(24.6%) were high-intermediate, and 23 (19.5%) were
high-risk. Information on IPI was not available in 5 pa-
tients. Median follow-up was 67 months (reverse
Kaplan-Meier method) and the overall 5-year PFS and
overall survival (OS) estimates were 65.7% and 68.9%,
respectively (Fig. 2 for IPI-specific survival curves).
Treatment regimens were R-CHOP (n = 104, 88.1%),
R-CHOEP (n = 12, 10.2%), and R-CEOP (n = 2, 1.7%).
Two patients turned out to be CD20 negative and thus
had rituximab removed from their treatment regimens.
The inter-observer agreement evaluated by Fleiss’
kappa was moderate at 0.47 when PET/CT readers
assessed prognosis (poor/favorable), whereas the agree-
ment for MTVvas and eMTV were good to excellent
with values of 0.81 and 0.66, respectively. Finally, moder-
ate to high correlations between automated MTV mea-
surements (MTV2.5, MTV41, TLG2.5, and TLG41) and
visual eMTV estimates were found, as shown in Table 1.
There was, however, no unanimous highest correlation
between the automated and visually assessed MTV
across the three reviewers.
Prediction of outcome using automated software
The areas under the ROC curves for 3-year PFS predic-
tions were 0.59, 0.54, 0.58, and 0.56 for MTV2.5, MTV41,
TLG2.5, and TLG41, respectively. The corresponding
values for 3-year OS predictions were 0.58, 0.53, 0.57,
and 0.54 for MTV2.5, MTV41, TLG2.5, and TLG41, re-
spectively. The best dichotomous cut-off values for PFS
based on tumor burden were 542ml, 147 ml, 3237, and
1485 for MTV2.5, MTV41, TLG2.5, and TLG41, respect-
ively. Corresponding values for OS were 585 ml, 105 ml,
3560 ml, and 2557 ml for MTV2.5, MTV41, TLG2.5, and
TLG41, respectively. Using these thresholds, only MTV2.5
was borderline associated with OS (log-rank p = 0.065)
and PFS (log-rank p = 0.11) (Fig. 2a and e), whereas
MTV41 was not associated with OS (log-rank p = 0.76) or
PFS (log-rank p = 0.67) (Fig. 2b and f). TLG2.5 (log-rank
p = 0.14) or TLG41 (log-rank p = 0.34) was not prognostic
in PFS or OS analyses.
Visual estimation of tumor volume
For MTVvas and eMTV, the areas under ROC curves for
the three reviewers for PFS and OS were 0.62, 0.63, and
0.58 and 0.61, 0.61, and 0.56 for MTVvas and 0.60, 0.62,
and 0.58 and 0.60, 0.60, and 0.56 for eMTV. Best
cut-offs for MTVvas were 4, 4, and 6 for both PFS and
OS. Best eMTV cut-off for high and low tumor burden
was 288, 450, and 425 ml for PFS and 288, 450, and
1250 ml for OS. Subsequent Kaplan-Meier analyses
showed that only the eMTV threshold for one of the re-
viewers (450 ml) could separate patients in high or low
risk (Kaplan-Meier log-rank p = 0.034 for PFS). However,
the areas under the ROC curves were comparable or
better for eMTV than for MTV. Table 3 shows the cor-
relation between eMTV of individual reviewers and the
semi-automated measurements, which was surprisingly
good for two reviewers.
Visual prognosis
The subjective visual assessments of prognosis (poor/fa-
vorable) were highly associated with outcomes both in
PFS and OS analyses for all three reviewers, and the
consensus prognosis for the three reviewers (all poor/
mixed/all favorable) also showed strong association (p <
0.01 for PFS and p = 0.01 for OS (Fig. 2d and g). For the
44 patients in the mixed group, the majority vote was
“poor” for 14 and “favorable” for the remaining 30.
Ranges of MTV2.5 were 287–8462, 8–2672, and 14–
2260 for “all poor,” “all favorable,” and “mixed” consen-
sus prognosis patients, respectively. The overlap in
tumor volume between patients classified by visual prog-
nosis underlines the importance of other factors than
tumor burden, when reviewers assessed prognosis.
Using the majority vote, the log-rank test also showed
significant differences between the two groups, differences
in 2-year survival were, however, larger when including a
mixed group, with differences between favorable and poor
of respectively 28% and 36% for OS and PFS using the
consensus diagnosis and differences of 23% and 26% for
OS and PFS using the majority vote (Fig. 3).
Table 2 IPI classification for patients. Pre-therapy IPI was
unavailable in five patients
Patient characteristics
Age 66 (16–88)
Ann Arbor I–II 40 (34%)
Ann Arbor III–IV 76 (64%)
Nodal > 1 31 (26%)
ECOG > 1 18 (15%)
LDL > UNL 62 (53%)
IPI > 2 52 (44%)
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Discussion
Understanding of DLBCL and the outcome diversity has
evolved substantially over the last decade, in particular
with the recognition of distinct and prognostic molecu-
lar genetic subtypes of DLBCL [13, 17], although none
of these classifications have well-established influence on
treatment decisions [18–21]. In parallel, the use of sta-
ging 18F-FDG PET/CT has enabled a more precise
estimate of total tumor volume, one of the historically
most important prognostic factors in lymphoma usually
determined indirectly by the Ann Arbor stage and/or
LDH level. Not surprisingly, most [14, 22–24] but not
all [25] studies have demonstrated tumor burden as an
adverse prognostic factor regardless of how the lymphoma
lesions are delineated. This has led to increased interest in
using automated measurements of pre-therapy MTV to
Fig. 2 Progression-free survival (PFS) and overall survival (OS) using automated metabolic tumor volume (MTV) measurements (a, b, e, f), IPI (c, g)
vs. visual assessment of prognosis by expert readers (d, h). As seen, the visual PET assessment of prognosis significantly outperformed both the
automated PET metrics as well as the prognosis by the treating hematologist (IPI)
Table 3 Pearson correlation between visually assessed eMTV and semi-automated measurements
eMTV—Pearson correlation
Reviewer 1 Reviewer 2 Reviewer 3 MTV2.5 MTV41 TLG2.5 TLG41
Reviewer 1 1.00 0.66 0.66 0.90 0.82 0.82 0.72
Reviewer 2 0.66 1.00 0.69 0.80 0.74 0.89 0.84
Reviewer 3 0.66 0.69 1.00 0.68 0.68 0.77 0.76
MTV2.5 0.90 0.80 0.68 1.00 0.92 0.89 0.79
MTV41 0.82 0.74 0.68 0.92 1.00 0.80 0.81
TLG2.5 0.82 0.89 0.77 0.89 0.80 1.00 0.95
TLG41 0.72 0.84 0.76 0.79 0.81 0.95 1.00
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guide treatment decisions, occasionally in combination
with already established response assessment criteria [14].
There are several examples of successful automated
scoring systems to report disease severity in the field of
pathology and radiology, e.g., Ki-67 index [26], brain at-
rophy by MRI [27], breast density by mammography
[28]. In general nuclear medicine, automatic scoring of
stress-induced myocardial ischemia by myocardial perfu-
sion imaging has been shown to perform as well as vis-
ual interpretation [29, 30]. However, in order to replace
expert analysis in routine practice, an automated tech-
nique should either outperform expert analysis or per-
form as well but with less human effort to avoid reader
fatigue. Currently, full measurement of lymphoma MTV
has some drawbacks that limit clinical implementation:
First, MTV measurements are time-consuming using
available software solutions. Second, consensus regard-
ing the best method for lymphoma lesion delineation
has not been reached. Third, it remains to be shown that
MTV measurements in DLBCL add prognostic information
over and above what can be determined from simple visual
image assessment and commonly used clinical risk scores.
We used Hermes TumorFinder to evaluate the two
most commonly used lesion delineation algorithms: one
based on a fixed threshold of SUV2.5 (MTV2.5) [14] and
one using a 41% of SUVmax isocontour (MTV41) [31].
Both methods require manual adjustments of segmenta-
tions provided by the software (e.g., cropping out of the
kidneys, ureters, bladder, liver, heart, and brain), which
took 10–15min on average per patient, similar to what
was reported in a previous study [32]. As detailed in
Fig. 2, MTV2.5 performed significantly better than
MTV41 in predicting PFS and OS, although we were un-
able to separate high- and low-risk groups as well as pre-
viously reported [14, 22–24]. This discrepancy may well
be explained by the ROC-based MTV2.5 cut-off for high
tumor burden, which in our cohort was approxi-
mately 550 ml. Others have reported markedly lower
cut-off values of ~ 400 ml [32] and 220 ml [24]. Im-
portantly, our cohort was relatively small and weak
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Fig. 3 Progression-free survival (PFS) and overall survival (OS) using the visual assessment of prognosis by expert readers. a, c The consensus
diagnosis of the three readers with an intermediate group reflecting disagreement between reviewers. b, d Prognosis based on majority decision.
As seen, both consensus and majority decisions were able to significantly identify high- and low-risk patients
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prognostic factors may have been missed due to the
risk of type II errors.
Our expert readers outperformed the automated pre-
diction of outcome when using all available information
from the PET/CT scans including visually estimated
MTV, heterogenous lesion pattern, and extra-nodal in-
volvement in a binary score (good/poor prognosis).
Moreover, they did so in less than a minute per patient
and therefore with far less effort and without the need
for additional software packages than a standard PET/
CT viewer. Interestingly, the three-decade old IPI classi-
fication based on simple clinical risk factors was as prog-
nostic as the automated MTV, although not on par with
the binary assessment of prognosis provided by the ex-
pert readers (Fig. 2).
The present study also points out the flaws of visual
image interpretation, in particular inter-observer vari-
ability. When asked to grade metabolic tumor volume
on a VAS, agreement among reviewers was poor (Fleiss’
kappa 0.28) and the consensus MTVvas could not satisfy-
ingly stratify patients into high- or low-risk groups. Our
reviewers were also unable to estimate absolute MTV in
milliliters (eMTV) to a level that reflected true measured
levels. In addition, although individual reviewers were
able to significantly prognosticate outcome on a dichot-
omous scale (poor/favorable prognosis), agreement
among reviewers was only moderate (Fleiss kappa 0.47).
In other words, our reviewers did not uniformly identify
the same patients as having a good or poor prognosis.
Conclusions
In summary, automated MTV measurements in DLBCL
are time-consuming and may not add prognostic infor-
mation over and above what is delivered in an unsuper-
vised expert analysis, which on the other hand is prone
to inter-reader variability and limited generalizability.
Importantly, this study is not intended to challenge, de-
valuate, or oppose the important progress made in the
use of quantitative PET/CT in lymphoma. However, it
highlights the fact that any prognostic information based
on automated measures should be held up against the
information obtained in an unsupervised clinical judg-
ment based on physician experience. In fact, a general
reminder that algorithms do not always outperform
good clinical judgment and that their value should be
tested against the unmeasurable knowledge of trained
clinical experts.
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